PPACA Impact and Opportunities for the Life Sciences Industry Explored
Overview:
Following the Supreme Court’s decision to upheld PPACA in August 2012, the year ahead opens new challenges and opportunities for the life sciences industry. Some of the factors that will directly impact the industry include taxes, rebates, and transparency requirements along with recent regulatory approvals. Life sciences companies must have a complete understanding of how to effectively thrive through the challenges and how to take advantage of the opportunities to minimize the potential pitfalls PPACA can bring to their bottom line.
In a two-hour LIVE webcast, a panel of thought leaders assembled by the Knowledge Group will discuss the significant issues in the mix including:
- Biologics Price Competition and Innovation Act (BPCIA)
- Medical Device Tax
- Sunshine Act
- Role of PCORI and IPAB
- Accountable Care Organization (ACO) Model
- Best Practices
- And a lot more!
Agenda:
Kevin R. Sweeney, Chair, Life Science Group,
Polsinelli Shughart PC
Dr. Steven K. Stranne, Shareholder,
Polsinelli Shughart PC
- Keeping up with developments in the area of health care reform can feel like drinking from a fire hose. This presentation provides a practical checklist and explanation of how to evaluate the issues that warrant attention for life sciences companies pursuing reimbursement and coverage strategies in the U.S. marketplace for drugs, biologics, devices and other technologies.
- Learn how the new reimbursement models emerging from the Center for Medicare and Medicaid Innovation are changing the financial incentives for health care providers and how to navigate the changing environment.
- Learn about how the evolving area of quality measurement is designed to change physician behavior and has implications for life sciences companies. Changes in the measurement of quality under Medicare are found in the health reform law (PPACA), the recent “fiscal cliff” legislation, and new legislative proposals.
- Learn how new provisions on the coverage of preventive screening services are relevant to the products used to perform preventive services, as well as diagnostics and therapies that may be clinically indicated on the basis of such screenings.
- Although the initiative to promote comparative effectiveness research in PPACA has been slow to develop, learn about why this topic deserves the attention of life sciences companies.
Terry Hisey, Vice Chairman and U.S. Life Sciences Leader,
Deloitte LLP
** Speaker Talking Points to be added soon.. **
Jerry Cacciotti, Partner,
Oliver Wyman Health & Life Sciences
** Speaker Talking Points to be added soon.. **
Who Should Attend:
- Biotech/Pharma Industry Lawyers
- Consultants
- Life Sciences and Health Care Practice Consultants/Advisors
- General Counsel
- Senior Management
- Senior Executives
- Accountants
- Professionals coming from Biotech and Pharmaceutical Firms
- Consultants & Clients in the Biotech and Pharmaceutical Industries
Kevin Sweeney is Chair of Polsinelli Shughart’s multidisciplinary Life Sciences practice group and a senior member of its Corporate Finance …
Steven K. Stranne is a physician and lawyer with over 18 years of experience in Washington, D.C. designing, implementing and …
R.T. (Terry) Hisey is the Vice Chairman and U.S. Life Sciences Leader for Deloitte LLP. In this role, Terry leads …
Jerry is a Partner in Oliver Wyman’s Health and Life Sciences Practice. He is a trusted advisor to senior executives …
Course Level:
Intermediate
Advance Preparation:
Print and review course materials
Method of Presentation:
On-demand Webcast (CLE)
Prerequisite:
NONE
Course Code:
124395
NASBA Field of Study:
NY Category of CLE Credit:
Total Credits:
2.0 CLE
Login Instructions:
No Access
You are not logged in. Please Login or register to the event to gain access to the materials and login instructions.
Unlock All The Knowledge and Credit You Need
Leading Provider of Online Continuing Education
It's As Easy as 1, 2, 3
Get Your 1-Year All Access Pass For Only $199
SPEAKERS' FIRMS:
About Polsinelli Shughart PC
Website: https://www.polsinelli.com/
About Deloitte LLP
The multidisciplinary strengths of Deloitte’s Life Sciences practice offer the comprehensive resources necessary to address the wide range of transformative issues affecting early-stage, emerging and established life sciences companies. From inception and incorporation, to an initial public offering or a new global product launch, our people have the experience that life sciences companies require to address the unique needs of their expanding business around the world.
About Oliver Wyman Health & Life Sciences
Oliver Wyman is a global leader in management consulting. With offices in 50+ cities across 25 countries, Oliver Wyman combines deep industry knowledge with specialized expertise in strategy, operations, risk management, and organization transformation. The firm’s 3,000 professionals help clients optimize their business, improve their operations and risk profile, and accelerate their organizational performance to seize the most attractive opportunities. Oliver Wyman is a wholly owned subsidiary of Marsh & McLennan Companies [NYSE: MMC]. For more information, visitwww.oliverwyman.com. Follow Oliver Wyman on Twitter @OliverWyman.
Website: https://www.oliverwyman.com/health-life-sciences.htm